**Supplementary table 5. Antibiotic FDCs combinations including two highest critically important antibiotics**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **FDC**  | **SU sold in 2015** | **US FDA approval** | **EML listed** | **Countries** |
| cefixime/ofloxacin | 0.31 x 109 | not | not | India |
| azithromycin/cefixime | 0.17 x 109 | not | not | India, Indonesia |
| azithromycin/levofloxacin | 0.02 x 109 | not | not | India |
| azithromycin/ofloxacin | 0.01 x 109 | not | not | India |
| cefixime/moxifloxacin | 0.02 x 108 | not | not | India |
| cefixime/levofloxacin | 0.07 x 107 | not | not | India |
| azithromycin/cefixime/*L. acidophilus* | 0.07 x 107 | not | not | India |
| cefixime//ofloxacin/ *L. acidophilus* | 0.04 x 107 | not | not | India |
| cefixime/cefpodoxime proxetil | 0.09 x 106 | not | not | India |
| ceftriaxone/vancomycin | 0.03 x 106 | not | not | India |